EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Herui Yao iD, Min Yan iD, Zhongsheng Tong, Xinhong Wu, Min-Hee Ryu iD, John J Park iD, Jee Hyun Kim iD, Yahua Zhong, Yiming Zhao, Mark Voskoboynik, Yongmei Yin, Kan Liu und 21 weitere

Journal of Clinical Oncology · 10.10.2024 · 42 (29) · 3453-3465

DOI: 10.1200/jco.23.02044 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2024. Verfasst von Herui Yao und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE SHR-A1811 is an antibody-drug conjugate composed of an anti–human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors. METHODS This global, multi-center, first-in-human, phase I trial was conducted at 33 centers. Patients who had HER2-expressing or mutated unresectable, advanced, or metastatic solid tumors and were refractory or intolerant to standard therapies were enrolled. SHR-A1811 was administered intravenously at doses ranging from 1.0 to 8.0 mg/kg once every 3 weeks. The primary end points were dose-limiting toxicity, safety, and the recommended phase II dose. RESULTS From September 7, 2020, to February 27, 2023, 307 patients who had undergone a median of three (IQR, 2-5) previous treatment regimens in the metastatic setting received SHR-A1811 treatment. As of data cutoff (February 28, 2023), one patient from the 6.4 mg/kg group experienced dose-limiting toxicities (pancytopenia and colitis). The most common grade 3 or higher adverse events (AEs) included decreased neutrophil count (119 [38.8%]) and decreased WBC count (70 [22.8%]). Interstitial lung disease occurred in only eight (2.6%) patients. Serious AEs and deaths occurred in 70 (22.8%) and 13 (4.2%) patients, respectively. SHR-A1811 led to objective responses in 59.9% (184/307) of all patients, 76.3% (90/118) of HER2-positive breast cancer, 60.4% (55/91) of HER2 low-expressing breast cancer, and 45.9% (39/85 with evaluable tumor responses) of the 98 nonbreast tumors. CONCLUSION SHR-A1811 exhibited acceptable tolerability, promising antitumor activity, and a favorable pharmacokinetic profile in heavily pretreated advanced solid tumors. The recommended phase II dose of 4.8 or 6.4 mg/kg was selected for various tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesNeoplasmsImmunoconjugatesHumansMiddle AgedFemaleMaleAgedAdultMutationAged, 80 and overMaximum Tolerated DoseAntineoplastic Agents, ImmunologicalTrastuzumabAntibodies, Monoclonal, Humanized

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesAntineoplastic Agents, ImmunologicalTrastuzumabAntibodies, Monoclonal, HumanizedERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for…
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Macquarie Medical School, Macquarie University, Sydney, NSW, Australia.

ORCID-Profile: Herui Yao, Min Yan, Min-Hee Ryu, John J Park, Jee Hyun Kim, Jian Zhang, Seock-Ah Im, Vinod Ganju, Li-Yuan Bai, Yung-Chang Lin, Lingying Wu, Erwei Song

Zitieren

APA

Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M. H., Park, J. J., Kim, J. H., Zhong, Y., Zhao, Y., Voskoboynik, M., Yin, Y., Liu, K., Kaubisch, A., Liu, C., Zhang, J., Wang, S., Im, S. A., Ganju, V., Barve, M., …, & Song, E. (2024). Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. Journal of Clinical Oncology, 42(29), 3453-3465. https://doi.org/10.1200/jco.23.02044

Vancouver

Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ, et al. Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. Journal of Clinical Oncology. 2024;42(29):3453-3465. doi:10.1200/jco.23.02044

BibTeX
@article{Yao2024,
  author = {Yao, Herui and Yan, Min and Tong, Zhongsheng and Wu, Xinhong and Ryu, Min-Hee and Park, John J and Kim, Jee Hyun and Zhong, Yahua and Zhao, Yiming and Voskoboynik, Mark and Yin, Yongmei and Liu, Kan and Kaubisch, Andreas and Liu, Caigang and Zhang, Jian and Wang, Shouman and Im, Seock-Ah and Ganju, Vinod and Barve, Minal and Li, Hui and Ye, Changsheng and Roy, Amitesh C and Bai, Li-Yuan and Yen, Chia-Jui and Gu, Shanzhi and Lin, Yung-Chang and Wu, Lingying and Bao, Lequn and Zhao, Kaijing and Shen, Yu and Rong, Shangyi and Zhu, Xiaoyu and Song, Erwei},
  title = {Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {29},
  pages = {3453--3465},
  doi = {10.1200/jco.23.02044}
}
Kostenlos starten →